Introduction One of the most dangerous organisms that cause major hospital acquired infections is P. aeruginosa. It is naturally resistant to many antimicrobial treatments, and the management of such infections…
Background Fungal infections are a major problem affecting over one billion people annually. Emerging pathogens and increasing resistance rates are complicating the situation, while new therapeutic options remain slow to…
Introduction The treatment of invasive fungal infections in liver transplant recipients is difficult because they are linked to increased morbidity and mortality. Despite a lack of clinical evidence, antifungal combination…
Introduction Triazole antifungals like voriconazole, posaconazole, and isavuconazole are used to treat invasive fungal infections like pulmonary aspergillosis. Triazoles inhibit cytochrome P450 enzymes (CYP450) and cause fungal cell death by…
Introduction Despite advancements in antifungal therapy over the last two decades, invasive fungal infections (IFIs) continue to be a major cause of morbidity and mortality among immunocompromised patients, particularly if…
Introduction Heme-containing peroxidases are widely distributed in the animal and plant kingdoms and play an important role in host defense by generating potent oxidants. Myeloperoxidase (MPO), the prototype of heme-containing…
Introduction Gram-negative bacteria cause two-thirds of infections in intensive care units (ICUs), and antibiotic resistance among these bacteria is a serious issue. Several multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii,…
Introduction Cryptococcus neoformans is a life-threatening invasive fungal disease. It is more than merely a multi-organ infection; the fungus' intracellular survival and extracellular proliferation play essential roles in the pathophysiology…
Introduction Candida glabrata is a new Candida species that causes infections ranging from minor to life-threatening systemic illness. Echinocandins and azoles are commonly employed as first-line therapy to treat C.…
Background In critically ill patients, the use of high tigecycline dosages (HD TGC) (200 mg/day) has been recently increasing but few pharmacokinetic/pharmacodynamic (PK/PD) data are available. We designed a prospective…